中华神经外科杂志
2025年 · 第41卷第02期
中华神经外科杂志
Glioma is the most common primary intracranial malignancy in adults. The annual incidence of glioma in China is 5/100,000~8/100,000. The most malignant glioblastoma has a lower 5-year survival rate than pancreatic and lung cancer, and has the worst survival prognosis among systemic malignancies. Although the precise diagnosis and treatment of glioma has made significant progress in recent years, the overall prognosis of patients is still not optimistic. It is particularly important to formulate scientific and standardized indicators of medical quality control (referred to as quality control) for glioma patients to improve the clinical management of the whole course of glioma patients, thus improving the quality of life of patients and prolonging the survival time of patients. Against this background, the National Center for Medical Quality Control of Neurological Diseases approved the establishment of a neurosurgical glioma disease group on July 19, 2024, and organized domestic experts and scholars in the field of glioma to jointly compile the Medical Quality Control Index of Glioma (2024 Edition). This quality control index system covers many aspects such as diagnosis accuracy, rationality of treatment plan, evaluation of treatment effect, complication control, etc., aiming to comprehensively evaluate the whole process of glioma diagnosis and treatment in a quantitative form, provide strong data support for the management and continuous improvement of medical quality, and ensure the overall improvement of glioma diagnosis and treatment quality. According to the Guidelines for Diagnosis and Treatment of Brain Glioma (2022 Edition), the Guidelines for Integrated Diagnosis and Treatment of Brain Glioma of China Anti-Cancer Association (2024 Edition), and the Guidelines for Clinical Management of Brain Glioma in China (2022 Edition), the specific quality control indicators are as follows.
本期目次


